Overall verdict
Sell
3.5/10
1-year performance
-21.53%
Score breakdown
Down 21.5% over 1 year, 15% of the 52-week range.
Strongest: Profitability 7.5/10. Weakest: Shareholder return 0.0/10.
Northwest Biotherapeutics, Inc., a biotechnology company, engages in the development of personalized immune therapies for cancer. The company develops DCVax, a platform technology which uses activated dendritic cells to mobilize a patient's own immune system to attack cancer. It also engages in the development of its lead product candidate DCVax-L in Phase III trials for glioblastoma multiforme brain cancer. In addition, the company develops DCVax-Direct in Phase I trials to treat inoperable solid tumors. Northwest Biotherapeutics, Inc. was founded in 1996 and is headquartered in Bethesda, Maryland.
Sector
Health Care
Industry
Biotechnology
Primary listing
Lse
United States
CEO
Linda Powers
Founded
1996
Employees
105
Revenue / employee
55 120 USD
Next earnings
—
Research uses the underlying stock’s market history. The purchase quote is calculated separately when you review your order.
52-week high
0.34 USD
52-week low
0.14 USD
1-year performance
-21.53%
Declining
Year-to-date performance
-33.82%
Declining
Drawdown
-50.22%
Major drawdown
Position in the 52-week range
15% of range
Against the world ETF
Over 25 years, from December 2001 to September 2026, the share did not clearly beat the world ETF once risk is accounted for. It earned less, while shaking 10.1 times harder.
$10,000 placed at the end of December 2001 are worth today
| NORTHWEST | $1 |
| World ETF | $76,565 |
| S&P 500 | $104,303 |
| Risk-free placement | $15,314 |
The risk
- Shaking:the share moves 10.1 times as much as the world ETF.
- Worst fall:-100 % between December 2001 and September 2026. $10,000 placed at the top fell to $1. The world ETF, at worst: -53 %. The share has not returned to its high yet.
NORTHWEST earned less than the world ETF since 2001
Value of $10,000 placed at the end of December 2001, dividends reinvested, in dollars
- NORTHWEST: $1
- World ETF: $76,565
- S&P 500: $104,303
- Risk-free placement: $15,314
Share price without dividends; the world ETF and the index reinvest theirs. A dividend payer is therefore understated here.
Based on past performance. This is not a recommendation.
Gross margin -39.0%, the company loses 1736.4% of its revenue, ROIC 275.6%, ROE 51.8%.
Net margin
-1736.36%
Negative
Sector -223.73%|S&P 13.15%
Gross margin
-39.02%
Negative
Return on equity (ROE)
51.84%
Exceptional
Sector -58.80%|S&P 16.61%
Return on invested capital (ROIC)
275.59%
Exceptional
Free cash flow margin (FCF)
-2290.34%
Negative
Margin stability
14339.3 pts
Very uneven
Revenue to net income
Growth
6.7/10Revenue up 535.4% over 1 year, 2.1% a year over 5.
Revenue (trailing 12 months)
2.2M USD
Revenue growth (1y)
535.41%
Hyper-growth
Revenue growth (3y)
-25.39%
Declining
EPS growth (1y)
—
EPS CAGR (5y)
—
EPS revisions (3 months)
—
Valuation
0.0/10The company loses money, so no valuation multiple can be read: a negative P/E is not a discount.
P/E (TTM)
—
N/A (loss)
Sector 11.4x|S&P 24.1x
Forward P/E (adjusted)
—
N/A (loss)
EV / EBITDA
—
N/A (loss)
Sector 14.4x|S&P 15.2x
PEG
—
Sector 1.09|S&P 0.90
Market cap
288M USD
Financial strength
5.0/10Cash covers 0.9% of the debt, net debt/EBITDA -1.1x.
Net debt / EBITDA
-1.1x
Net cash
Gearing (net debt / equity)
—
Cash
595 000 USD
Cash / market cap
0.21%
Stretched
Cash / total debt
0.94%
Stretched
Interest coverage
-5.3x
Stretched
Net debt
62.5M USD
Equity
-34.7M USD
Closed daily candles, 2 years
Last close on October 21, 2026: 0.17 USD
- MM200.16
- MM500.17
- MM2000.20
- RSI 1459.2
Top panel: closed candles, 20, 50 and 200-day moving averages, with volume in grey. Bottom panel: 14-day RSI with dashed 30 and 70 levels.
200-day average slope, 1 month
-4.34%
200-day average slope, 3 months
-10.33%
50-day average slope, 1 month
-3.63%
Price structure
Lower lows
Bullish RSI divergence
No
20-day volatility
2.76 % per day
Volatility change
-16.97%
Forecasts by fiscal year
| Fiscal year | EPS | Normalised EPS | Revenue | EBITDA | Net income |
|---|---|---|---|---|---|
| 2026 | — | -0.05 (1) | 0 (1) | — | — |
| 2027 | — | -0.07 (1) | 39 (1) | — | — |
Amounts in millions of USD, EPS in USD per share. In brackets, the number of analysts. Consensus as of July 13, 2026.
Same sub-industry: 781 companies behind the medians.
| # | Company | Code | Country | Overall / 10 | Fundamentals / 10 | Mkt cap | P/E | Net margin | Revenue growth | ROIC | Net debt / EBITDA | FCF yield | 1-year perf. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | AGEN | 5.6 | 4.9 | 289M USD | 2.4x | 69.3 % | 34.4 % | -11.7 % | 6.7x | -34.1 % | 44.8 % | ||
| 2 | SRZN | 5.5 | 4.3 | 298M USD | Not meaningful (loss) | -3042.9 % | 408.6 % | — | 2.2x | -11.8 % | 87.6 % | ||
| 3 | 6915 | 4.9 | 4.9 | 285M USD | — | — | 6.7 % | — | -0.7x | — | -7.8 % | ||
| 4 | PRLD | 4.7 | 3.5 | 291M USD | Not meaningful (loss) | -269.7 % | 73.4 % | -50.5 % | 2.0x | -11.4 % | 182.9 % | ||
| 5 | BNTC | 4.4 | N/A | 297M USD | Not meaningful (loss) | — | — | -33.1 % | 3.5x | -5.9 % | -46.2 % | ||
| 6 | NWBO | 3.5 | 4.0 | 288M USD | Not meaningful (loss) | -1736.4 % | 535.4 % | 275.6 % | -1.1x | -17.3 % | -21.5 % | ||
| 7 | IPSC | 3.4 | 1.5 | 292M USD | Not meaningful (loss) | -100.6 % | 1556.8 % | -41.9 % | 0.9x | -30.2 % | 182.2 % | ||
| 8 | XFOR | 3.2 | 3.0 | 298M USD | Not meaningful (loss) | -568.8 % | 346.3 % | -57.6 % | 1.5x | — | -4.4 % | ||
| 9 | A376900 | 2.7 | 3.0 | 279M USD | Not meaningful (loss) | -38.7 % | 36.6 % | -161.2 % | -7.1x | -6.0 % | -46.6 % |
